ASX:MSBBiotechs
Mesoblast Advances CAR Cell Therapy Platform And Late Stage Pain Trial
Mesoblast (ASX:MSB) has secured exclusive global rights to a patented CAR technology platform from Mayo Clinic for use with its mesenchymal stromal cell therapies.
The company has completed patient recruitment for its pivotal Phase 3 clinical trial of rexlemestrocel-L in chronic low back pain.
Both developments relate to Mesoblast’s cell therapy pipeline for immune and inflammatory disorders.
Mesoblast, trading at A$2.22, sits in a part of the market where individual clinical and licensing...